

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 January 2022 (20.01.2022)



(10) International Publication Number
WO 2022/013696 A3

(51) International Patent Classification:

C07K 14/55 (2006.01) A61K 39/395 (2006.01)
A61K 35/768 (2015.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2021/056192

(22) International Filing Date:

09 July 2021 (09.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/051,628 14 July 2020 (14.07.2020) US
63/051,890 14 July 2020 (14.07.2020) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **BINDER, Joseph John**; c/o Pfizer Inc., 10777
Science Center Drive, San Diego, California 92121 (US).
EISENBRAUN, Michael Dale; c/o Pfizer Inc., 10777
Science Center Drive, San Diego, California 92121 (US).
LEES, Clare; c/o Pfizer Inc., 10777 Science Center Drive,
San Diego, California 92121 (US). **MYERS, Jeremy
Shawn**; P.O. Box 404, Farmington, Connecticut 06034
(US). **PATTERSON, James Travis**; c/o Pfizer Inc., 10777
Science Center Drive, San Diego, California 92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd
Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(88) Date of publication of the international search report:

24 February 2022 (24.02.2022)

(54) Title: RECOMBINANT VACCINIA VIRUS

(57) Abstract: The present disclosure provides human IL-2 variants, recombinant oncolytic viruses comprising the IL-2 variant, compositions comprising the IL-2 variant or recombinant oncolytic virus, and use of the IL-2 variants, recombinant oncolytic virus, or compositions for treating cancer in an individual.



WO 2022/013696 A3